Literature DB >> 2791190

Reversal of multidrug resistance by new dihydropyridines with lower calcium antagonistic activity.

T Yoshinari1, Y Iwasawa, K Miura, I S Takahashi, T Fukuroda, K Suzuki, A Okura.   

Abstract

BS compounds, a series of new dihydropyridines, successfully overcame multidrug resistance in P388/ADR cells in vitro. These agents synergistically potentiated the cytotoxicity of Adriamycin to P388/ADR cells at a concentration of 1-2 microM, whereas they showed hardly any synergistic effect in the parental cell line (P388/S) at the same concentration. They inhibited the active drug efflux in P388/ADR cells as well as the binding of [G-3H]-vinblastine to membrane vesicles from P388/ADR, which was increased in resistant P388 cells as compared with parental cells. Besides, unlike the activity of clinically used calcium antagonists, the calcium antagonistic activity associated with BS compounds was very weak: their arterial relaxation activity was less than 21% of that of verapamil. These data suggest that BS compounds specifically overcome multidrug resistance without the serious hypotensive side effects that accompany the use of verapamil or other calcium antagonists.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2791190     DOI: 10.1007/bf00257444

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Kinetic analysis of active efflux of vincristine from multidrug-resistant P388 leukemia cells.

Authors:  M Inaba; T Watanabe; Y Sugiyama
Journal:  Jpn J Cancer Res       Date:  1987-04

2.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.

Authors:  T Tsuruo; H Iida; M Nojiri; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

3.  Phase I study of vinblastine and verapamil given by concurrent iv infusion.

Authors:  A B Benson; D L Trump; J M Koeller; M I Egorin; E A Olman; R S Witte; T E Davis; D C Tormey
Journal:  Cancer Treat Rep       Date:  1985 Jul-Aug

4.  Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line.

Authors:  M Nakagawa; S Akiyama; T Yamaguchi; N Shiraishi; J Ogata; M Kuwano
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

5.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

Authors:  M Inaba; H Kobayashi; Y Sakurai; R K Johnson
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

6.  Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells.

Authors:  E Friche; T Skovsgaard; N I Nissen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines.

Authors:  A Fojo; S Akiyama; M M Gottesman; I Pastan
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

Review 8.  Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics.

Authors:  T Tsuruo
Journal:  Cancer Treat Rep       Date:  1983-10

9.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

10.  Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.

Authors:  D Kessel; C Wilberding
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

View more
  6 in total

1.  Reversal of multidrug resistance by phenothiazines and structurally related compounds.

Authors:  A Ramu; N Ramu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 3.  Putative therapeutic applications of calmodulin antagonists.

Authors:  R Mannhold; H Timmerman
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

4.  Novel mechanism of N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine in potentiation of antitumor drug action on multidrug-resistant and sensitive Chinese hamster cells.

Authors:  A Tomida; T Tatsuta; H Suzuki
Journal:  Jpn J Cancer Res       Date:  1991-01

5.  Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukaemia in mice.

Authors:  A Kiue; T Sano; A Naito; M Okumura; K Kohno; M Kuwano
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

6.  Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro.

Authors:  A Kiue; T Sano; A Naito; H Inada; K Suzuki; M Okumura; J Kikuchi; S Sato; H Takano; K Kohno
Journal:  Jpn J Cancer Res       Date:  1990-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.